Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial
- Citation:
- Ann Oncol vol 28 (5) 1070-77
- Year:
- 2017
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Pharmas:
- Grants:
- K22CA188163, U10CA025224, U10CA037347, U10CA037404, U10CA047577, U10CA076001, U10CA077440, U10CA180790, U10CA180833, U10CA180857, U10CA180858, U10CA180870, U10CA180821, U10CA180882, U54HG003079
- Corr. Author:
- Authors:
- R. Lesurf O. L. Griffith M. Griffith J. Hundal L. Trani M. A. Watson R. Aft M. J. Ellis D. Ota V. J. Suman F. Meric-Bernstam A. M. Leitch J. C. Boughey G. Unzeitig A. U. Buzdar K. K. Hunt E. R. Mardis
- Networks:
- LAPS-MN026, LAPS-MO011, LAPS-TX011, LAPS-TX035, TX041, TX190
- Study
- ACOSOG-Z1041
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: